Abstract
BackgroundImmune checkpoint blockade (ICB) with αPD1, αPDL2, αCTLA4 and αLag3 is FDA-approved but agents fail to treat up to ~80% of all cancers. PDL2 is a second PD1 ligand1 but...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
